Long-term survival after autologous peripheral blood stem cell transplantation in two patients with malignant rhabdoid tumor of the kidney

Pediatric Blood and Cancer

Volumn 52, Issue 7, 2009, Pages 888-890

  Koga, Yuhki ^a   Matsuzaki, Akinobu ^a   Suminoe, Aiko ^a   Hatano, Miho ^a   Saito, Yusuke ^a   Kinoshita, Yoshiaki ^a   Tajiri, Tatsuro ^a   Taguchi, Tomoaki ^a   Kohashi, Kenichi ^a   Oda, Yoshinao ^a   Tsuneyoshi, Masazumi ^a   Hara, Toshiro ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Kidney; MRTK; Rhabdoid tumor; Stem cell transplantation

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTOKERATIN; DACTINOMYCIN; DOXORUBICIN; EPITHELIAL MEMBRANE ANTIGEN; ETOPOSIDE; HEMOGLOBIN; IFOSFAMIDE; LACTATE DEHYDROGENASE; MELPHALAN; NEUROFILAMENT PROTEIN; VIMENTIN; VINCRISTINE;

ABDOMINAL DISTENSION; ABDOMINAL MASS; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CHILD; COMPUTER ASSISTED TOMOGRAPHY; CRYOPRESERVATION; EXON; FOLLOW UP; GENE DELETION; HEMATURIA; HEMOGLOBIN BLOOD LEVEL; HISTOLOGY; HUMAN; INFANT; JAPANESE; KIDNEY TUMOR; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MULTIPLE CYCLE TREATMENT; NEPHROBLASTOMA; POSTOPERATIVE CARE; PRESCHOOL CHILD; PRIORITY JOURNAL; RENOGRAPHY; RHABDOID TUMOR; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IFOSFAMIDE; INFANT; KIDNEY NEOPLASMS; MALE; MELPHALAN; PROGNOSIS; RHABDOID TUMOR; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VINCRISTINE;

EID: 67650499564     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21958     Document Type: Article

References (19)

1. Weeks DA, Beckwith JB, Mierau GW, et al. Rhabdoid tumor of kidney. A report of 111 cases from the National Wilms Tumor Study Pathology Center. Am J Surg Pathol 1989;13:439-458. (Pubitemid 19149607)
2. Tomlinson GE, Breslow NE, Dome J, et al. Rhabdoid tumor of the kidney in the National Wilms Tumor Study: Age at diagnosis as a prognostic factor. J Clin Oncol 2005;23:7641-7645. (Pubitemid 46291828)
3. Ahmed HU, Arya M, Levitt G, et al. Part I: Primary malignant non-Wilms renal tumours in children. Lancet Oncol 2007;8:730-737. (Pubitemid 47177161)
4. D'Angio GJ, Breslow N, Beckwith JB, et al. Treatment of Wilms tumor. Results of the Third National Wilms Tumor Study. Cancer 1989;64:349-360.
5. Ahmed HU, Arya M, Levitt G, et al. Part II: Treatment of primary malignant non-Wilms renal tumours in children. Lancet Oncol 2007;8:842-848. (Pubitemid 47315502)
6. Madigan CE, Armenian SH, Malogolowkin MH, et al. Extracranial malignant rhabdoid tumors in childhood: The Childrens Hospital Los Angeles experience. Cancer 2007;110:2061-2066. (Pubitemid 350036867)
7. van den Heuvel-Eibrink MM, Grundy P, Graf N, et al. Characteristics and survival of 750 children diagnosed with a renal tumor in the first seven months of life: A collaborative study by the SIOP/GPOH/SFOP, NWTSG, and UKCCSGWilms tumor study groups. Pediatr Blood Cancer 2008;50:1130-1134.
8. Waldron PE, Rodgers BM,Kelly MD, et al. Successful treatment of a patient with stage IV rhabdoid tumor of the kidney: Case report and review. J Pediatr Hematol Oncol 1999;21:53-57. (Pubitemid 29131996)
9. Wagner L, Hill DA, Fuller C, et al. Treatment of metastatic rhabdoid tumor of the kidney. J Pediatr Hematol Oncol 2002;24: 385-388. (Pubitemid 34774010)
10. Yamamoto M, Suzuki N, Hatakeyama N, et al. Treatment of stage IV malignant rhabdoid tumor of the kidney (MRTK) with ICE and VDCy: A case report. J Pediatr Hematol Oncol 2006;28:286-289. (Pubitemid 43916708)
11. Sahdev I, James-Herry A, Scimeca P, et al. Concordant rhabdoid tumor of the kidney in a set of identical twins with discordant outcomes. J Pediatr Hematol Oncol 2003;25:491-494. (Pubitemid 36682757)
12. Kohashi K, Oda Y, Yamamoto H, et al. Highly aggressive behavior of malignant rhabdoid tumor: A special reference to SMARCB1/ INI1 gene alterations using molecular genetic analysis including quantitative real-time PCR. J Cancer Res Clin Oncol 2007;133: 817-824. (Pubitemid 350218907)
13. Green DM, Breslow NE, Beckwith JB, et al. Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms tumor: A report from the National Wilms Tumor Study Group. J Clin Oncol 1998;16:237-245. (Pubitemid 28041604)
14. Abu-Ghosh AM, Krailo MD, Goldman SC, et al. Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms tumor: A Children's Cancer Group report. Ann Oncol 2002;13:460-469. (Pubitemid 34705009)
15. Perentesis J, Katsanis E, DeFor T, et al. Autologous stem cell transplantation for high-risk pediatric solid tumors. Bone Marrow Transplant 1999;24:609-615. (Pubitemid 29446134)
16. Campbell AD, Cohn SL, Reynolds M, et al. Treatment of relapsed Wilms tumor with high-dose therapy and autologous hematopoietic stem-cell rescue: The experience at Children's Memorial Hospital. J Clin Oncol 2004;22:2885-2890. (Pubitemid 41079908)
17. Gardner SL, Asgharzadeh S, Green A, et al. Intensive induction chemotherapy followed by high dose chemotherapy with autologous hematopoietic progenitor cell rescue in young children newly diagnosed with central nervous system atypical teratoid rhabdoid tumors. Pediatr Blood Cancer 2008;51:235-240. (Pubitemid 351874418)
18. Gidwani P, Levy A, Goodrich J, et al., Successful outcome with tandem myeloablative chemotherapy and autologous peripheral blood stem cell transplants in a patient with atypical teratoid/ rhabdoid tumor of the central nervous system. J Neurooncol 2008; 88:211-215.
19. Brennan BM, Foot AB, Stiller C, et al. Where to next with extracranial rhabdoid tumours in children. Eur J Cancer 2004;40: 624-626. (Pubitemid 38220783)